drugset / Trial / NCT00002383

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

NCT00002383 ↗

Phase 1 Completed 80 enrolled Hoffmann-La Roche
Treatment

Summary

To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Saquinavir Small molecule 400 mg Oral
Subject Saquinavir Small molecule 600 mg Oral
Subject Saquinavir Small molecule 800 mg Oral
Subject Saquinavir Small molecule 1200 mg Oral